Delcath Systems Inc., a New York-based interventional oncology company dedicated to the treatment of primary and metastatic liver cancers, marked a substantial milestone with the launch and first commercial utilization of the HEPZATO KIT in the United States. The innovative medical treatment kit’s premier use in the commercial setting was noted on January 16, 2024.
Aimed predominantly towards the treatment of metastatic uveal melanoma, a rare cancer that begins in the eye and subsequently spreads to other parts of the body, the HEPZATO KIT underpins Delcath Systems’ focus on developing unique therapies for cancers in the liver.
Uveal melanoma, which forms in the uveal tract’s melanocyte cells, is marked by the aggressive proclivity to metastasize to the liver. Approximately 50% of affected patients develop metastatic diseases in the liver, often leading to death within a year after the metastatic diagnosis, making the efficient treatment of these patients a medical priority.
The successful commercial launch of the HEPZATO KIT indicates a significant advancement in Delcath System’s concerted efforts to expand their oncology solutions, focusing on primary and metastatic liver cancers. The interventional oncology company trades on the Nasdaq under the ticker symbol DCTH. Detailed specifics around the financial implications or the commercial performance of the HEPZATO KIT thus far were not released in the company’s announcement.
The pioneering use of the HEPZATO KIT for commercial treatment marks an important stride in the fight against metastatic uveal melanoma, potentially paving the way for better survival rates for patients suffering from this rare and aggressive form of cancer.
Comments